Serafina Mammoliti

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 144 citations

Carboplatin-based Doublet, Medicine, Metronomic Therapy +7

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites

Nicoletta Colombo, Giorgia Mangili, Serafina Mammoliti et al. · Gynecologic Oncology · 2011 · 94 citations

Medicine, Cancer Management, Phase Ii Study +6

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.

Pierfranco Conté, Milena Bruzzone, F Carnino et al. · Journal of Clinical Oncology · 1996 · 90 citations

Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage IB–IIA1)

Pierangelo Marchiolè, J Tigaud, S. Costantini et al. · Gynecologic Oncology · 2011 · 81 citations

Infertility, Cervical Cancer Management, Gynecologic Surgery +13